JP7345886B2 - Alcohol-containing composition - Google Patents
Alcohol-containing composition Download PDFInfo
- Publication number
- JP7345886B2 JP7345886B2 JP2021086582A JP2021086582A JP7345886B2 JP 7345886 B2 JP7345886 B2 JP 7345886B2 JP 2021086582 A JP2021086582 A JP 2021086582A JP 2021086582 A JP2021086582 A JP 2021086582A JP 7345886 B2 JP7345886 B2 JP 7345886B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mass
- acid
- present
- foam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 99
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims description 62
- -1 sorbitan fatty acid ester Chemical class 0.000 claims description 55
- 239000006260 foam Substances 0.000 claims description 47
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 23
- 229930195729 fatty acid Natural products 0.000 claims description 23
- 239000000194 fatty acid Substances 0.000 claims description 23
- 239000002736 nonionic surfactant Substances 0.000 claims description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 17
- 235000011187 glycerol Nutrition 0.000 claims description 11
- 229920001296 polysiloxane Polymers 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 239000003093 cationic surfactant Substances 0.000 claims description 8
- 150000005215 alkyl ethers Chemical class 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 6
- 238000007599 discharging Methods 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 229940008099 dimethicone Drugs 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims 2
- 229910001431 copper ion Inorganic materials 0.000 claims 2
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 description 39
- 230000014759 maintenance of location Effects 0.000 description 27
- 238000004659 sterilization and disinfection Methods 0.000 description 22
- 150000003839 salts Chemical class 0.000 description 21
- 230000000249 desinfective effect Effects 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 239000003906 humectant Substances 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 102100031673 Corneodesmosin Human genes 0.000 description 8
- 101710139375 Corneodesmosin Proteins 0.000 description 8
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 7
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000000645 desinfectant Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 210000004247 hand Anatomy 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000000174 gluconic acid Substances 0.000 description 4
- 235000012208 gluconic acid Nutrition 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000012723 sample buffer Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- HQHCYKULIHKCEB-UHFFFAOYSA-N tetradecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCC(O)=O HQHCYKULIHKCEB-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241001678559 COVID-19 virus Species 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 229940105990 diglycerin Drugs 0.000 description 3
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 229960004585 etidronic acid Drugs 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- ZFGOPJASRDDARH-UHFFFAOYSA-N 3-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C(C2)C1(C)CCC2OC1CC2=CCC3C4CCC(C(C)CCCC(C)C)C4(C)CCC3C2(C)CC1 ZFGOPJASRDDARH-UHFFFAOYSA-N 0.000 description 2
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 241001263478 Norovirus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 229940073499 decyl glucoside Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 102000048657 human ACE2 Human genes 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003915 liquefied petroleum gas Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
- MFYAQFYIDXXKQG-MLCQCVOFSA-N (2s)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-(hexadecanoylamino)-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O MFYAQFYIDXXKQG-MLCQCVOFSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- GOLAKLHPPDDLST-AVQMFFATSA-N (9e,12e)-octadeca-9,12-dien-1-amine Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCN GOLAKLHPPDDLST-AVQMFFATSA-N 0.000 description 1
- GOLAKLHPPDDLST-HZJYTTRNSA-N (9z,12z)-octadeca-9,12-dien-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCN GOLAKLHPPDDLST-HZJYTTRNSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- RUDVQBCFUZDOTA-AATRIKPKSA-N (e)-hex-1-en-1-amine Chemical compound CCCC\C=C\N RUDVQBCFUZDOTA-AATRIKPKSA-N 0.000 description 1
- LPMBTLLQQJBUOO-KTKRTIGZSA-N (z)-n,n-bis(2-hydroxyethyl)octadec-9-enamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N(CCO)CCO LPMBTLLQQJBUOO-KTKRTIGZSA-N 0.000 description 1
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 1
- POKOASTYJWUQJG-UHFFFAOYSA-M 1-butylpyridin-1-ium;chloride Chemical compound [Cl-].CCCC[N+]1=CC=CC=C1 POKOASTYJWUQJG-UHFFFAOYSA-M 0.000 description 1
- YAYNEUUHHLGGAH-UHFFFAOYSA-N 1-chlorododecane Chemical compound CCCCCCCCCCCCCl YAYNEUUHHLGGAH-UHFFFAOYSA-N 0.000 description 1
- GKQHIYSTBXDYNQ-UHFFFAOYSA-M 1-dodecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+]1=CC=CC=C1 GKQHIYSTBXDYNQ-UHFFFAOYSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IEORSVTYLWZQJQ-UHFFFAOYSA-N 2-(2-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=CC=C1OCCO IEORSVTYLWZQJQ-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- CRWNQZTZTZWPOF-UHFFFAOYSA-N 2-methyl-4-phenylpyridine Chemical compound C1=NC(C)=CC(C=2C=CC=CC=2)=C1 CRWNQZTZTZWPOF-UHFFFAOYSA-N 0.000 description 1
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 1
- RIAJTMUAPNIDSS-UHFFFAOYSA-N 3-aminopropan-1-ol;hydron;chloride Chemical compound Cl.NCCCO RIAJTMUAPNIDSS-UHFFFAOYSA-N 0.000 description 1
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RUPBZQFQVRMKDG-UHFFFAOYSA-M Didecyldimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC RUPBZQFQVRMKDG-UHFFFAOYSA-M 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- JJOJFIHJIRWASH-UHFFFAOYSA-N Eicosanedioic acid Natural products OC(=O)CCCCCCCCCCCCCCCCCCC(O)=O JJOJFIHJIRWASH-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WYUFTYLVLQZQNH-JAJWTYFOSA-N Ethyl beta-D-glucopyranoside Chemical compound CCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WYUFTYLVLQZQNH-JAJWTYFOSA-N 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000484121 Human parvovirus Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 244000280244 Luffa acutangula Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 240000000366 Melilotus officinalis Species 0.000 description 1
- 235000017822 Melilotus officinalis Nutrition 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- 108010075308 N-palmitoyl-seryl-seryl-asparaginyl-alanine Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241001537205 Paracoccidioides Species 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 244000014047 Polianthes tuberosa Species 0.000 description 1
- 235000016067 Polianthes tuberosa Nutrition 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 229940126247 SARS-CoV-2 inhibitor Drugs 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- PLZVEHJLHYMBBY-UHFFFAOYSA-N Tetradecylamine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000005703 Trimethylamine hydrochloride Substances 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003254 anti-foaming effect Effects 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229940094978 bis-peg-18 methyl ether dimethyl silane Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000963 caseinolytic effect Effects 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 108010006161 conchiolin Proteins 0.000 description 1
- QYQADNCHXSEGJT-UHFFFAOYSA-N cyclohexane-1,1-dicarboxylate;hydron Chemical compound OC(=O)C1(C(O)=O)CCCCC1 QYQADNCHXSEGJT-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- HXWGXXDEYMNGCT-UHFFFAOYSA-M decyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)C HXWGXXDEYMNGCT-UHFFFAOYSA-M 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960004670 didecyldimethylammonium chloride Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- XXBDWLFCJWSEKW-UHFFFAOYSA-N dimethylbenzylamine Chemical compound CN(C)CC1=CC=CC=C1 XXBDWLFCJWSEKW-UHFFFAOYSA-N 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- OGNIRUSROLJRSJ-UHFFFAOYSA-N dodec-1-en-1-amine Chemical compound CCCCCCCCCCC=CN OGNIRUSROLJRSJ-UHFFFAOYSA-N 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 229940012466 egg shell membrane Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940007062 eucalyptus extract Drugs 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 229940074046 glyceryl laurate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- LAPRIVJANDLWOK-UHFFFAOYSA-N laureth-5 Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCO LAPRIVJANDLWOK-UHFFFAOYSA-N 0.000 description 1
- 229940031957 lauric acid diethanolamide Drugs 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- XGZOMURMPLSSKQ-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N(CCO)CCO XGZOMURMPLSSKQ-UHFFFAOYSA-N 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- YYELLDKEOUKVIQ-UHFFFAOYSA-N octaethyleneglycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO YYELLDKEOUKVIQ-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- AQZSPJRLCJSOED-UHFFFAOYSA-M trimethyl(octyl)azanium;chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(C)C AQZSPJRLCJSOED-UHFFFAOYSA-M 0.000 description 1
- CEYYIKYYFSTQRU-UHFFFAOYSA-M trimethyl(tetradecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)C CEYYIKYYFSTQRU-UHFFFAOYSA-M 0.000 description 1
- SZYJELPVAFJOGJ-UHFFFAOYSA-N trimethylamine hydrochloride Chemical compound Cl.CN(C)C SZYJELPVAFJOGJ-UHFFFAOYSA-N 0.000 description 1
- 229940113165 trimethylolpropane Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、低級アルコール並びにノニオン界面活性剤を含有する組成物に関する。 The present invention relates to a composition containing a lower alcohol and a nonionic surfactant.
例年、インフルエンザウイルスやノロウイルス等、様々なウイルスによる感染症が問題となっている。これらの感染症は、飛沫感染や接触感染で感染が拡大する。感染拡大を防ぐための対策として消毒液による手指の消毒が重要であるが、その多くは液状である。消毒液を手指に均一に塗布するためには、多量に噴霧又は塗布するケースが多い。また、消毒液は、使用時に手指から液剤が流れ落ちてしまう現象(液だれ)が生じるため、液の一部が無駄になる、衣服や床などを汚すといった原因となる。また、消毒液をゲル状にした組成物も開発されている(例えば特許文献1)。ゲル状組成物では、液だれは生じにくいものの、塗布後にべたつきが残る、均一な塗布が難しいといった課題がある。また、近年では均一な塗布を目的とし、フォーム状の組成物が開発されているが、有効成分である低級アルコールは消泡作用を有することから、低級アルコールを含有しながらも、泡持ちが良く、均一に塗布できる組成物の開発が求められている。 Every year, infectious diseases caused by various viruses such as influenza virus and norovirus have become a problem. These infectious diseases spread through droplet infection and contact infection. Disinfecting hands with disinfectant is important as a measure to prevent the spread of infection, but most of these are in liquid form. In order to uniformly apply disinfectant to hands and fingers, a large amount is often sprayed or applied. Furthermore, when using a disinfectant, a phenomenon occurs in which the solution runs down from the hands and fingers (dripping), which results in a portion of the solution being wasted and staining clothes, floors, etc. Furthermore, a gel composition of a disinfectant has also been developed (for example, Patent Document 1). Although gel-like compositions are less prone to dripping, there are problems in that they remain sticky after application and are difficult to apply uniformly. In addition, in recent years, foam-like compositions have been developed for the purpose of uniform application, but since the lower alcohol, which is an active ingredient, has an antifoaming effect, it has good foam retention even though it contains lower alcohol. There is a need to develop a composition that can be applied uniformly.
本発明の課題は、低級アルコールを含有しながらも、泡持ちが良く、使用感に優れた組成物を提供することにある。 An object of the present invention is to provide a composition that has good foam retention and an excellent feel when used, even though it contains a lower alcohol.
本出願人は、上記課題を解決するために、種々の物質について鋭意検討を積み重ねたところ、驚くべきことに、低級アルコール並びにノニオン界面活性剤を含有する本発明の組成物は、フォーマー容器から泡状に吐出させたところ泡持ちが良く、液だれが起こらず、優れた使用感であることを見出した。また、本出願人は、上記課題を解決するために、種々の物質について鋭意検討を積み重ねたところ、驚くべきことに、本発明の組成物は、低級アルコールを高濃度含有するにもかかわらず、フォーマー容器から泡状に吐出させたところ泡持ちが良く、液だれが起こらず、優れた使用感であることを見出した。本発明は、かかる知見に基づき、完成された発明である。 In order to solve the above problems, the present applicant has conducted intensive studies on various substances, and surprisingly, the composition of the present invention containing a lower alcohol and a nonionic surfactant has been found to be able to remove foam from a foamer container. It was found that the foam had good foam retention, no dripping occurred, and had an excellent feeling of use. In addition, in order to solve the above problems, the present applicant has conducted intensive studies on various substances, and surprisingly, the composition of the present invention, despite containing a high concentration of lower alcohol, When the foam was discharged from a foamer container, it was found that the foam had good retention, no dripping occurred, and had an excellent feeling of use. The present invention has been completed based on this knowledge.
本発明の概要は、以下の通りである。
<1>フォーマー容器から泡状に吐出させて使用される組成物であって、低級アルコール及びノニオン界面活性剤を含有し、前記低級アルコールの含有量が30~60質量% であることを特徴とする組成物。
<2>前記ノニオン界面活性剤がポリオキシエチレンアルキルエーテル、ポリオキシエチレンポリオキシプロピレンアルキルエーテル、ポリオキシアルキレンソルビタン脂肪酸エステル、ポリグリセリン脂肪酸エステル、ショ糖脂肪酸エステル、グリセリン脂肪酸エステル、ポリエーテル変性シリコーンから選ばれる少なくとも1種であることを特徴とする<1>に記載の組成物。
<3>酸又はその塩を含有することを特徴とする、<1>又は<2>のいずれかに記載の組成物。
<4>さらに、カチオン界面活性剤を含有することを特徴とする、<1>~<3>のいずれかに記載の組成物。
<5>さらに、水を含有する<1>~<4>のいずれかに記載の組成物。
<6>さらに、保湿剤を含有する<1>~<5>のいずれかに記載の組成物。
<7>皮膚の殺菌、除菌、消毒用であることを特徴とする、<1>~<6>のいずれかに記載の組成物。
<8>硬質表面の殺菌、除菌、消毒用であることを特徴とする、<1>~<6>のいずれかに記載の組成物。
The outline of the present invention is as follows.
<1> A composition that is used by discharging it in the form of a foam from a foamer container, containing a lower alcohol and a nonionic surfactant, and characterized in that the content of the lower alcohol is 30 to 60% by mass. composition.
<2> The nonionic surfactant is polyoxyethylene alkyl ether, polyoxyethylene polyoxypropylene alkyl ether, polyoxyalkylene sorbitan fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, glycerin fatty acid ester, polyether-modified silicone The composition according to <1>, which is at least one selected from the group consisting of:
<3> The composition according to any one of <1> or <2>, which contains an acid or a salt thereof.
<4> The composition according to any one of <1> to <3>, further comprising a cationic surfactant.
<5> The composition according to any one of <1> to <4>, further containing water.
<6> The composition according to any one of <1> to <5>, further containing a humectant.
<7> The composition according to any one of <1> to <6>, which is used for sterilizing, disinfecting, and disinfecting the skin.
<8> The composition according to any one of <1> to <6>, which is used for sterilizing, sterilizing, and disinfecting hard surfaces.
本発明によれば、泡持ちが良いために液だれが起こらず、使用感に優れた組成物を得ることができる。特に、本発明によれば、低級アルコールを高濃度含有するにもかかわらず、泡持ちが良いために液だれが起こらず、使用感に優れた組成物を得ることができる。また、本発明の組成物は手指など皮膚の殺菌、除菌、消毒だけでなく、硬質表面でも使用できることから、接触感染拡大防止効果が期待できる。 According to the present invention, it is possible to obtain a composition that has good foam retention, does not cause dripping, and has an excellent feeling of use. In particular, according to the present invention, it is possible to obtain a composition that has good foam retention, does not cause dripping, and has an excellent feel when used, despite containing a high concentration of lower alcohol. Furthermore, since the composition of the present invention can be used not only for sterilizing, sterilizing, and disinfecting the skin of hands and fingers, but also for hard surfaces, it can be expected to be effective in preventing the spread of contact infection.
以下、本発明を詳細に説明する。 The present invention will be explained in detail below.
[1.低級アルコール]
本発明は、低級アルコールを必須成分とする。本発明において使用できる低級アルコールとしては、通常皮膚外用剤として使用されるものであれば特に制限されず、例えば、エタノール、イソプロパノールが挙げられる。本発明においては、泡持ちや使用時の塗布の容易さ、均一さなどといった使用感と、殺菌、除菌、消毒作用の両立の観点から、エタノールが好ましい。
[1. Lower alcohol]
The present invention uses a lower alcohol as an essential component. The lower alcohol that can be used in the present invention is not particularly limited as long as it is normally used as an external skin preparation, and examples thereof include ethanol and isopropanol. In the present invention, ethanol is preferred from the viewpoint of both the feeling of use such as foam retention, ease of application, and uniformity during use, and the sterilization, sterilization, and disinfection effects.
本発明で使用する低級アルコールは、1種のみを使用しても良いし、2種以上を用いることもできる。本発明の組成物に配合される低級アルコールの含有量としては泡持ちや使用時の塗布の容易さ、均一さなどといった使用感と、殺菌、除菌、消毒作用の両立の観点から、例えば、30質量%、好ましくは35質量%以上、より好ましくは40質量%以上の範囲で選択される。また、同様の観点から、消毒剤の含有量は、例えば95質量%以下、好ましくは60質量%以下、より好ましくは55質量%以下、特に好ましくは50質量%以下の範囲で選択される。但し、低級アルコールを2種以上含有する場合は、その総量である。 The lower alcohols used in the present invention may be used alone or in combination of two or more. The content of the lower alcohol to be blended into the composition of the present invention is determined from the viewpoint of both feeling of use such as foam retention, ease of application, and uniformity during use, and sterilization, sterilization, and disinfection effects, for example: It is selected in a range of 30% by mass, preferably 35% by mass or more, more preferably 40% by mass or more. Further, from the same viewpoint, the content of the disinfectant is selected within a range of, for example, 95% by mass or less, preferably 60% by mass or less, more preferably 55% by mass or less, particularly preferably 50% by mass or less. However, if two or more kinds of lower alcohols are contained, the amount is the total amount.
[2.ノニオン界面活性剤]
本発明の組成物は、低級アルコールと共にノニオン界面活性剤を含有することを特徴とする。低級アルコールと共にノニオン界面活性剤を配合することにより、泡持ちや使用時の塗布の容易さ、均一さなどといった使用感と、殺菌、除菌、消毒作用の両立が可能となる。
[2. Nonionic surfactant]
The composition of the present invention is characterized by containing a nonionic surfactant together with a lower alcohol. By blending a nonionic surfactant with a lower alcohol, it is possible to achieve both a feeling of use such as foam retention, ease of application, and uniformity during use, as well as sterilizing, sterilizing, and disinfecting effects.
ノニオン性界面活性剤としては、例えば、ラウリン酸グリセリン、モノステアリン酸グリセリンなどのグリセリン脂肪酸エステル;ソルビタン脂肪酸エステル;ペンタエチレングリコールモノドデシルエーテル、オクタエチレングリコールモノドデシルエーテル、ポリオキシエチレンノニルフェニルエーテル、ポリオキシエチレンオレイルエーテル、ポリオキシエチレンステアリルエーテル、ポリオキシエチレンラウリルエーテル、ポリオキシエチレンセチルエーテル、ポリオキシエチレンベヘニルエーテル、ポリオキシエチレン2-ヘキシルデシルエーテル、ポリオキシエチレンオクチルドデシルエーテル、ポリオキシエチレンコレステリルエーテルなどのポリオキシエチレンアルキルアリールエーテルあるいはポリオキシエチレンアルキルエーテル;ポリオキシエチレンポリオキシプロピレンデシルテトラデシルエーテル、ポリオキシエチレンポリオキシプロピレンセチルエーテルなどのポリオキシエチレンポリオキシプロピレンアルキルエーテル;ポリオキシエチレンアルキルフェニルエーテル、オクチルフェノールエトキシレート、ノニルフェノールエトキシレートなどのアルキルフェノールアルキレート;ポリオキシエチレンポリオキシプロピレングリコールなどのポリオキシアルキレングリコール;ポリオキシエチレンソルビタン脂肪酸エステル、モノステアリン酸ポリオキシエチレンソルビタン、ポリオキシエチレンヘキシタン脂肪酸エステル、ソルビタン脂肪酸エステルポリエチレングリコールなどのポリオキシアルキレンソルビタン脂肪酸エステル;ポリエチレングリコールモノラウレート、ポリエチレングリコ-ルモノステアレート、ポリエチレングリコールモノオレエート等のポリオキシアルキレン脂肪酸エステル;モノラウリン酸ポリグリセリル、モノステアリン酸ポリグリセリルなどのポリグリセリン脂肪酸エステル;ステアリン酸スクロースなどのショ糖脂肪酸エステル;カプリル酸グリセリルなどのグリセリン脂肪酸エステル;ラウリン酸ジエタノールアミド、オレイン酸ジエタノールアミド、ステアリン酸ジエタノールアミド、コカミドDEAなどのアルカノールアミド;オクチルグルコシド、デシルグルコシド、ラウリルグルコシドなどのアルキルグルコシド;オキシエチレン/オキシプロピレンブロックコポリマー;フッ素系界面活性剤;ポリグリセリル変性シリコーン、ジグリセル変性シリコーン、グリセリル変性シリコーン、糖変性シリコーン、ポリエーテル変性シリコーン(PEG/PPG-25/25ジメチコン、ビス(PEG/PPG-20/20)ジメチコン、ビスPEG-18メチルエーテルジメチルシラン、PEG-12ジメチコン)、カルボン酸変性シリコーン等のシリコーン系界面活性剤;デシルグルコシド、ラウリルグリコシド等のアルキルグリコシド等が挙げられ、泡持ちや使用時の塗布の容易さ、均一さなどといった使用感と、殺菌、除菌、消毒作用の両立の観点から、ポリオキシエチレンアルキルエーテル、ポリオキシエチレンポリオキシプロピレンアルキルエーテル、ポリオキシアルキレンソルビタン脂肪酸エステル、ポリグリセリン脂肪酸エステル、ショ糖脂肪酸エステル、グリセリン脂肪酸エステル、ポリエーテル変性シリコーンが好ましく、ポリオキシエチレンアルキルエーテルが特に好ましい。 Examples of nonionic surfactants include glycerin fatty acid esters such as glyceryl laurate and glyceryl monostearate; sorbitan fatty acid esters; pentaethylene glycol monododecyl ether, octaethylene glycol monododecyl ether, polyoxyethylene nonylphenyl ether, and Oxyethylene oleyl ether, polyoxyethylene stearyl ether, polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene behenyl ether, polyoxyethylene 2-hexyldecyl ether, polyoxyethylene octyl dodecyl ether, polyoxyethylene cholesteryl ether polyoxyethylene alkylaryl ether or polyoxyethylene alkyl ether such as; polyoxyethylene polyoxypropylene alkyl ether such as polyoxyethylene polyoxypropylene decyl tetradecyl ether, polyoxyethylene polyoxypropylene cetyl ether; polyoxyethylene alkylphenyl Alkylphenol alkylates such as ether, octylphenol ethoxylate, nonylphenol ethoxylate; polyoxyalkylene glycols such as polyoxyethylene polyoxypropylene glycol; polyoxyethylene sorbitan fatty acid ester, polyoxyethylene sorbitan monostearate, polyoxyethylene hexitane fatty acid ester, sorbitan fatty acid ester Polyoxyalkylene sorbitan fatty acid ester such as polyethylene glycol; polyoxyalkylene fatty acid ester such as polyethylene glycol monolaurate, polyethylene glycol monostearate, polyethylene glycol monooleate; polyglyceryl monolaurate, polyglyceryl monostearate Polyglycerin fatty acid esters such as; sucrose fatty acid esters such as sucrose stearate; glycerin fatty acid esters such as glyceryl caprylate; alkanolamides such as lauric acid diethanolamide, oleic acid diethanolamide, stearic acid diethanolamide, and cocamide DEA; octyl glucoside , alkyl glucosides such as decyl glucoside and lauryl glucoside; oxyethylene/oxypropylene block copolymers; fluorosurfactants; polyglyceryl-modified silicones, diglycel-modified silicones, glyceryl-modified silicones, sugar-modified silicones, polyether-modified silicones (PEG/PPG- Silicone surfactants such as 25/25 dimethicone, bis(PEG/PPG-20/20) dimethicone, bis PEG-18 methyl ether dimethylsilane, PEG-12 dimethicone), carboxylic acid-modified silicone; decyl glucoside, lauryl glycoside, etc. Polyoxyethylene alkyl ether, polyoxyethylene polyamide, Oxypropylene alkyl ether, polyoxyalkylene sorbitan fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, glycerin fatty acid ester, and polyether-modified silicone are preferred, and polyoxyethylene alkyl ether is particularly preferred.
本発明において界面活性剤を使用する場合、界面活性剤は1種のみを使用しても良いし、2種以上を用いることもできる。本発明の組成物に界面活性剤を配合する場合、その含有量としては泡持ちや使用時の塗布の容易さ、均一さなどといった使用感と、殺菌、除菌、消毒作用の両立ができる範囲であれば特に制限はなく、その含有量を適宜設定できる。例えば、0.0001質量%、好ましくは0.001質量%以上、より好ましくは0.005質量%以上の範囲で選択される。また、同様の観点から、界面活性剤の含有量は、例えば15質量%以下、好ましくは10質量%以下、より好ましくは8質量%以下、特に好ましくは5質量%以下の範囲で選択される。但し、界面活性剤を2種以上含有する場合は、その総量である。本発明においては、市販品を使用してもよく、また当該分野で公知の方法で製造したものを使用することもできる。 When using a surfactant in the present invention, only one type of surfactant may be used, or two or more types may be used. When a surfactant is added to the composition of the present invention, the content should be within a range that provides both a feeling of use such as foam retention, ease of application, and uniformity during use, as well as sterilizing, sterilizing, and disinfecting effects. If so, there is no particular restriction, and the content can be set as appropriate. For example, it is selected in the range of 0.0001% by mass, preferably 0.001% by mass or more, more preferably 0.005% by mass or more. Further, from the same viewpoint, the content of the surfactant is selected within a range of, for example, 15% by mass or less, preferably 10% by mass or less, more preferably 8% by mass or less, particularly preferably 5% by mass or less. However, if two or more types of surfactants are contained, the amount is the total amount. In the present invention, commercially available products may be used, or products manufactured by methods known in the art may also be used.
[3.酸又はその塩]
本発明の組成物は、酸又はその塩を配合することが好ましい。酸又はその塩を配合することにより、組成物の安定性が向上すると共に、泡の安定性向上も可能となる。本発明の組成物において使用できる酸又はその塩としては特に制限されず、通常pH調整に使用する酸又はその塩を使用することができる。具体的には、有機酸又はその塩、無機酸又はその塩が挙げられ、塩酸、硫酸、リン酸、硝酸等の無機酸又はその塩;ギ酸、酢酸、プロピオン酸、スルファミン酸、グルコン酸、アスコルビン酸、フェルラ酸、コハク酸、フィチン酸、乳酸、クエン酸、リンゴ酸、マレイン酸、マロン酸、カプリル酸、アジピン酸、フマル酸、エチドロン酸、エデト酸又はこれらの塩を挙げることができ、好ましくは塩酸、硫酸、乳酸、グルコン酸、コハク酸、クエン酸、リンゴ酸、エチドロン酸、エデト酸及びリン酸又はこれらの塩であり、より好ましくは塩酸、硫酸、乳酸、グルコン酸、クエン酸、リンゴ酸、エチドロン酸、エデト酸及びリン酸又はこれらの塩である。
[3. acid or its salt]
The composition of the present invention preferably contains an acid or a salt thereof. By blending an acid or a salt thereof, the stability of the composition is improved, and it is also possible to improve the stability of the foam. The acid or salt thereof that can be used in the composition of the present invention is not particularly limited, and acids or salts thereof that are commonly used for pH adjustment can be used. Specifically, organic acids or their salts, inorganic acids or their salts are mentioned; inorganic acids or their salts such as hydrochloric acid, sulfuric acid, phosphoric acid, and nitric acid; formic acid, acetic acid, propionic acid, sulfamic acid, gluconic acid, and ascorbic acid. Preferred examples include ferulic acid, succinic acid, phytic acid, lactic acid, citric acid, malic acid, maleic acid, malonic acid, caprylic acid, adipic acid, fumaric acid, etidronic acid, edetic acid, or salts thereof. is hydrochloric acid, sulfuric acid, lactic acid, gluconic acid, succinic acid, citric acid, malic acid, etidronic acid, edetic acid, phosphoric acid, or salts thereof, and more preferably hydrochloric acid, sulfuric acid, lactic acid, gluconic acid, citric acid, apple acids, etidronic acid, edetic acid and phosphoric acid or salts thereof.
本発明において酸又はその塩を使用する場合、酸又はその塩は1種のみを使用しても良いし、2種以上を用いることもできる。本発明の組成物に酸又はその塩を配合する場合、その含有量としては泡持ちや使用時の塗布の容易さ、均一さなどといった使用感と、殺菌、除菌、消毒作用の両立ができる範囲であれば特に制限はなく、その含有量を適宜設定できる。例えば、0.0001質量%、好ましくは0.0005質量%以上、より好ましくは0.001質量%以上の範囲で選択される。また、同様の観点から、酸又はその塩の含有量は、例えば20質量%以下、好ましくは15質量%以下、より好ましくは10質量%以下の範囲で選択される。但し、酸又はその塩を2種以上含有する場合は、その総量である。本発明においては、市販品を使用してもよく、また当該分野で公知の方法で製造したものを使用することもできる。 When using acids or salts thereof in the present invention, only one type of acid or salt thereof may be used, or two or more types thereof may be used. When an acid or a salt thereof is added to the composition of the present invention, the content thereof is such that it can provide both a feeling of use such as foam retention, ease of application, and uniformity during use, as well as sterilizing, sterilizing, and disinfecting effects. There is no particular restriction as long as it is within the range, and the content can be set as appropriate. For example, it is selected in the range of 0.0001% by mass, preferably 0.0005% by mass or more, more preferably 0.001% by mass or more. Further, from the same viewpoint, the content of the acid or its salt is selected within a range of, for example, 20% by mass or less, preferably 15% by mass or less, and more preferably 10% by mass or less. However, if two or more types of acids or salts thereof are contained, the amount is the total amount. In the present invention, commercially available products may be used, or products manufactured by methods known in the art may also be used.
[4.カチオン性界面活性剤]
本発明の組成物は、カチオン性界面活性剤を配合することが好ましい。カチオン性界面活性剤としては、例えば、オレイルアミン、ステアリルアミン、テトラデシルアミン、1-ヘキセニルアミン、1-ドデセニルアミン、9,12-オクタデカジエニルアミン(リノールアミン)、9,12,15-オクタデカトリエニルアミン、リノレイルアミン等の、アルキルアミンなどの脂肪族アミン;塩化テトラメチルアンモニウム、水酸化テトラメチルアンモニウム、塩化テトラブチルアンモニウム、塩化アルキルトリメチルアンモニウム、塩化オクチルトリメチルアンモニウム、塩化デシルトリメチルアンモニウム、塩化ドデシルトリメチルアンモニウム、塩化テトラデシルトリメチルアンモニウム、塩化セチルトリメチルアンモニウム、塩化ステアリルトリメチルアンモニウム、臭化アルキルトリメチルアンモニウム、臭化ヘキサデシルトリメチルアンモニウム、塩化ベンジルトリメチルアンモニウム、塩化ベンジルトリエチルアンモニウム、塩化ベンザルコニウム(塩化ドデシルジメチルベンジルアンモニウム)、臭化ベンザルコニウム、塩化ベンゼトニウム、塩化ジデシルジメチルアンモニウム、塩化ジステアリルジメチルアンモニウムなどの第四級アンモニウム塩;塩化ブチルピリジニウム、塩化ドデシルピリジニウム、塩化セチルピリジニウムなどのアルキルピリジニウム塩;モノメチルアミン塩酸塩、ジメチルアミン塩酸塩、トリメチルアミン塩酸塩などの脂肪族アミン塩;等が挙げられる。本発明においては、第四級アンモニウム塩が好ましく、泡持ちや使用時の塗布の容易さ、均一さなどといった使用感と、殺菌、除菌、消毒作用の両立の観点から、塩化ベンザルコニウムが特に好ましい。
[4. Cationic surfactant]
The composition of the present invention preferably contains a cationic surfactant. Examples of the cationic surfactant include oleylamine, stearylamine, tetradecylamine, 1-hexenylamine, 1-dodecenylamine, 9,12-octadecadienylamine (linolamine), 9,12,15-octadecadienylamine, Aliphatic amines such as alkylamines, such as trienylamine and linoleylamine; tetramethylammonium chloride, tetramethylammonium hydroxide, tetrabutylammonium chloride, alkyltrimethylammonium chloride, octyltrimethylammonium chloride, decyltrimethylammonium chloride, chloride Dodecyltrimethylammonium, Tetradecyltrimethylammonium chloride, Cetyltrimethylammonium chloride, Stearyltrimethylammonium chloride, Alkyltrimethylammonium bromide, Hexadecyltrimethylammonium bromide, Benzyltrimethylammonium chloride, Benzyltriethylammonium chloride, Benzalkonium chloride (Dodecyl chloride) quaternary ammonium salts such as dimethylbenzylammonium), benzalkonium bromide, benzethonium chloride, didecyldimethylammonium chloride, distearyldimethylammonium chloride; alkylpyridinium salts such as butylpyridinium chloride, dodecylpyridinium chloride, cetylpyridinium chloride; Aliphatic amine salts such as monomethylamine hydrochloride, dimethylamine hydrochloride, and trimethylamine hydrochloride; and the like. In the present invention, quaternary ammonium salts are preferable, and benzalkonium chloride is preferable from the viewpoint of both feeling of use such as foam retention, ease of application, and uniformity during use, and sterilization, sterilization, and disinfection effects. Particularly preferred.
[5.水]
本発明の組成物は、低級アルコール及びノニオン界面活性剤に加えて水を含有することができる。本発明の組成物に水を配合する場合、その含有量としては泡持ちや使用時の塗布の容易さ、均一さなどといった使用感と、殺菌、除菌、消毒作用の両立ができる範囲であれば特に制限はなく、その含有量を適宜設定できる。例えば、1質量%、好ましくは10質量%以上、より好ましくは20質量%以上の範囲で選択される。また、同様の観点から、水の含有量は、例えば80質量%以下、好ましくは75質量%以下、より好ましくは70質量%以下の範囲で選択される。
[5. water]
The composition of the present invention can contain water in addition to the lower alcohol and nonionic surfactant. When water is added to the composition of the present invention, the content should be within a range that provides both a feeling of use such as foam retention, ease of application, and uniformity during use, as well as sterilizing, sterilizing, and disinfecting effects. There are no particular restrictions, and the content can be set as appropriate. For example, it is selected in the range of 1% by mass, preferably 10% by mass or more, more preferably 20% by mass or more. Further, from the same viewpoint, the water content is selected within a range of, for example, 80% by mass or less, preferably 75% by mass or less, and more preferably 70% by mass or less.
[6.保湿剤]
本発明の組成物は、低級アルコールに加えて保湿剤を含有することができる。使用できる保湿剤としては、例えば、グリセリン、1,3-ブチレングリコール、プロピレングリコール、3-メチル-1,3-ブタンジオール、1,3-プロパンジオール、2-メチル-1,3-プロパンジオール、トリメチロールプロパン、ペンタエリスリトール、ヘキシレングリコール、ジグリセリン、ポリグリセリン、ジエチレングリコール、ポリエチレングリコール、ジプロピレングリコール、ポリプロピレングリコール、エチレングリコール・プロピレングリコール共重合体等のポリオール類及びその重合体;ジエチレングリコールモノエチルエーテル(エトキシジグリコール)、エチレングリコールモノエチルエーテル、エチレングリコールモノブチルエーテル、ジエチレングリコールジブチルエーテル等のグリコールアルキルエーテル類;(エイコサン二酸/テトラデカン二酸)ポリグリセリル-10、テトラデカン二酸ポリグリセリル-10、シクロヘキサンジカルボン酸ビスエトキシジグリコール等の水溶性エステル類;ソルビトール、キシリトール、エリスリトール、マンニトール、マルチトール等の糖アルコール類;グルコース、フルクトース、ガラクトース、マンノース、トレオース、キシロース、アラビノース、フコース、リボース、デオキシリボース、マルトース、トレハロース、ラクトース、ラフィノース、グルコン酸、グルクロン酸、シクロデキストリン類(α-、β-、γ-シクロデキストリン、及び、マルトシル化、ヒドロキシアルキル化等の修飾シクロデキストリン)、β-グルカン、キチン、キトサン、ヘパリン及び誘導体、ペクチン、アラビノガラクタン、デキストリン、デキストラン、グリコーゲン、エチルグルコシド、メタクリル酸グルコシルエチル重合物若しくは共重合物等の糖類及びその誘導体類;ヒアルロン酸、ヒアルロン酸ナトリウム;コンドロイチン硫酸ナトリウム;ムコイチン硫酸、カロニン硫酸、ケラト硫酸、デルマタン硫酸;シロキクラゲ抽出物、シロキクラゲ多糖体;イヌリン、レバン等のフルクタン類;フコイダン;チューベロース多糖体、天然由来多糖体;クエン酸、酒石酸、乳酸等の有機酸及びその塩;尿素;2-ピロリドン-5-カルボン酸及びそのナトリウム等の塩;ベタイン(トリメチルグリシン)、プロリン、ヒドロキシプロリン、アルギニン、リジン、セリン、グリシン、アラニン、フェニルアラニン、チロシン、β-アラニン、スレオニン、グルタミン酸、グルタミン、アスパラギン、アスパラギン酸、システイン、シスチン、メチオニン、ロイシン、イソロイシン、バリン、トリプトファン、ヒスチジン、タウリン等のアミノ酸類及びその塩;コラーゲン、魚由来コラーゲン、アテロコラーゲン、ゼラチン、エラスチン、コラーゲン分解ペプチド、加水分解コラーゲン、塩化ヒドロキシプロピルアンモニウム加水分解コラーゲン、エラスチン分解ペプチド、ケラチン分解ペプチド、加水分解ケラチン、コンキオリン分解ペプチド、加水分解コンキオリン、シルク蛋白分解ペプチド、加水分解シルク、ラウロイル加水分解シルクナトリウム、大豆蛋白分解ペプチド、小麦蛋白分解ペプチド、加水分解小麦蛋白、カゼイン分解ペプチド、アシル化ペプチド等の蛋白ペプチド類及びその誘導体;パルミトイルオリゴペプチド、パルミトイルペンタペプチド、パルミトイルテトラペプチド等のアシル化ペプチド類;シリル化ペプチド類;乳酸菌培養液、酵母抽出液、卵殻膜タンパク、牛顎下腺ムチン、ヒポタウリン、ゴマリグナン配糖体、グルタチオン、アルブミン、乳清;塩化コリン、ホスホリルコリン;胎盤抽出液、エアラスチン、コラーゲン、アロエ抽出物、ハマメリス水、ヘチマ水、カモミラエキス、カンゾウエキス、コンフリーエキス、シルクエキス、イザヨイバラエキス、セイヨウノコギリソウエキス、ユーカリエキス、メリロートエキス等の動物・植物抽出成分;天然型セラミド(タイプ1、2、3、4、5、6)、ヒドロキシセラミド、疑似セラミド、スフィンゴ糖脂質、セラミド及び糖セラミド含有エキス等のセラミド類;等が挙げられる。その中でも、ポリオール類及びその重合体、糖アルコール類が好ましく、グリセリン、1,3-ブチレングリコール、プロピレングリコール、3-メチル-1,3-ブタンジオール、1,3-プロパンジオール、ジグリセリンがより好ましい。
[6. Moisturizer]
The composition of the invention can contain a humectant in addition to the lower alcohol. Humectants that can be used include, for example, glycerin, 1,3-butylene glycol, propylene glycol, 3-methyl-1,3-butanediol, 1,3-propanediol, 2-methyl-1,3-propanediol, Polyols and their polymers such as trimethylolpropane, pentaerythritol, hexylene glycol, diglycerin, polyglycerin, diethylene glycol, polyethylene glycol, dipropylene glycol, polypropylene glycol, ethylene glycol/propylene glycol copolymer; diethylene glycol monoethyl ether Glycol alkyl ethers such as (ethoxydiglycol), ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, diethylene glycol dibutyl ether; (eicosandioic acid/tetradecanedioic acid) polyglyceryl-10, tetradecanedioic acid polyglyceryl-10, cyclohexanedicarboxylic acid Water-soluble esters such as bisethoxydiglycol; sugar alcohols such as sorbitol, xylitol, erythritol, mannitol, maltitol; glucose, fructose, galactose, mannose, threose, xylose, arabinose, fucose, ribose, deoxyribose, maltose, Trehalose, lactose, raffinose, gluconic acid, glucuronic acid, cyclodextrins (α-, β-, γ-cyclodextrin, and modified cyclodextrins such as maltosylation and hydroxyalkylation), β-glucan, chitin, chitosan, Saccharides and their derivatives such as heparin and derivatives, pectin, arabinogalactan, dextrin, dextran, glycogen, ethyl glucoside, glucosylethyl methacrylate polymers or copolymers; hyaluronic acid, sodium hyaluronate; sodium chondroitin sulfate; mucoitin sulfate , caronine sulfate, keratosulfate, dermatan sulfate; white fungus extract, white fungus polysaccharide; fructans such as inulin and levan; fucoidan; tuberose polysaccharide, naturally derived polysaccharides; organic acids such as citric acid, tartaric acid, lactic acid, and their salts ; Urea; 2-pyrrolidone-5-carboxylic acid and its salts such as sodium; betaine (trimethylglycine), proline, hydroxyproline, arginine, lysine, serine, glycine, alanine, phenylalanine, tyrosine, β-alanine, threonine, glutamic acid , glutamine, asparagine, aspartic acid, cysteine, cystine, methionine, leucine, isoleucine, valine, tryptophan, histidine, taurine, and other amino acids and their salts; collagen, fish-derived collagen, atelocollagen, gelatin, elastin, collagen-degrading peptide, hydration Degraded collagen, hydroxypropylammonium chloride hydrolyzed collagen, elastin-degraded peptide, keratin-degraded peptide, hydrolyzed keratin, conchiolin-degraded peptide, hydrolyzed conchiolin, silk proteolytic peptide, hydrolyzed silk, sodium lauroyl hydrolyzed silk, soybean proteolytic peptide , protein peptides such as wheat proteolytic peptide, hydrolyzed wheat protein, caseinolytic peptide, acylated peptide, and derivatives thereof; acylated peptides such as palmitoyl oligopeptide, palmitoyl pentapeptide, palmitoyl tetrapeptide; silylated peptides; Lactic acid bacteria culture solution, yeast extract, eggshell membrane protein, bovine submandibular gland mucin, hypotaurine, sesame lignan glycoside, glutathione, albumin, whey; choline chloride, phosphorylcholine; placenta extract, aerastin, collagen, aloe extract, Hamamelis Animal and plant extract ingredients such as water, loofah water, chamomilla extract, licorice extract, comfrey extract, silk extract, rose thorn extract, yarrow extract, eucalyptus extract, melilot extract; natural ceramides (types 1, 2, 3, 4) , 5, 6), ceramides such as hydroxyceramide, pseudoceramide, glycosphingolipid, ceramide, and sugar ceramide-containing extract. Among these, polyols, polymers thereof, and sugar alcohols are preferred, and glycerin, 1,3-butylene glycol, propylene glycol, 3-methyl-1,3-butanediol, 1,3-propanediol, and diglycerin are more preferred. preferable.
本発明において保湿剤を使用する場合、保湿剤は1種のみを使用しても良いし、2種以上を用いることもできる。本発明の組成物に保湿剤を配合する場合、その含有量としては泡持ちや使用時の塗布の容易さ、均一さなどといった使用感と、殺菌、除菌、消毒作用の両立ができる範囲であれば特に制限はなく、その含有量を適宜設定できる。例えば、0.01質量%、好ましくは0.05質量%以上、より好ましくは0.1質量%以上の範囲で選択される。また、同様の観点から、保湿剤の含有量は、例えば20質量%以下、好ましくは15質量%以下、より好ましくは8質量%以下、特に好ましくは10質量%以下の範囲で選択される。但し、保湿剤を2種以上含有する場合は、その総量である。本発明においては、市販品を使用してもよく、また当該分野で公知の方法で製造したものを使用することもできる。 When using a humectant in the present invention, only one type of humectant may be used, or two or more types may be used. When a moisturizer is added to the composition of the present invention, the content should be within a range that provides both a feeling of use such as foam retention, ease of application, and uniformity during use, as well as sterilizing, sterilizing, and disinfecting effects. If so, there is no particular restriction, and the content can be set as appropriate. For example, it is selected in the range of 0.01% by mass, preferably 0.05% by mass or more, more preferably 0.1% by mass or more. Further, from the same viewpoint, the content of the humectant is selected within a range of, for example, 20% by mass or less, preferably 15% by mass or less, more preferably 8% by mass or less, particularly preferably 10% by mass or less. However, if two or more types of humectants are contained, the amount is the total amount. In the present invention, commercially available products may be used, or products manufactured by methods known in the art may also be used.
[6.フォーマー容器]
本発明の組成物は、フォーマー容器に充填されて使用されるものであり、フォーマー容器から泡状に吐出されて使用されることを特徴とする。フォーマー容器とは、吐出時に組成物と気体とを一定割合にて混合することで泡を形成できる容器である。吐出時に組成物と混合され、泡を形成する気体としては、例えば、空気;液化石油ガス(LPG)、ジメチルエーテルなどの液化ガス;二酸化炭素、窒素、亜酸化窒素などの圧縮ガス;等が挙げられる。吐出方法は特に限定されず、容器の構造に応じて適宜選択でき、例えば、ノズル部分を押す、ボトル本体を握る等により圧をかける;赤外線などのセンサーにより対象物を感知し、吐出する;噴射ボタンを押す、握る等により容器内の組成物と噴霧ガスとを混合し、吐出する;等の方法が挙げられる。吐出量は吐出方法に応じて適宜変更できる。本発明においては、殺菌、除菌、消毒作用の観点からノズル部分を押す構造、又は赤外線などのセンサーにより対象物を感知し、吐出する構造のフォーマー容器を用いることが好ましい。また、フォーマー容器は蓋を取り外して組成物を充填することにより、繰り返し使用できる構造であることが、経済的な観点から好ましい。
[6. Former container]
The composition of the present invention is used by being filled into a foamer container, and is characterized in that it is used by being discharged from the foamer container in the form of a foam. A foamer container is a container that can form foam by mixing a composition and gas at a certain ratio during discharge. Examples of gases that are mixed with the composition and form bubbles during discharge include air; liquefied gases such as liquefied petroleum gas (LPG) and dimethyl ether; compressed gases such as carbon dioxide, nitrogen, and nitrous oxide; and the like. . The dispensing method is not particularly limited and can be selected as appropriate depending on the structure of the container.For example, pressure is applied by pressing the nozzle part, gripping the bottle body, etc.; Sensing the object with an infrared sensor etc. and discharging; Spraying Examples of methods include mixing the composition in the container and the atomizing gas and discharging the mixture by pressing or squeezing a button. The discharge amount can be changed as appropriate depending on the discharge method. In the present invention, from the viewpoint of sterilization, sterilization, and disinfection, it is preferable to use a former container having a structure in which the nozzle part is pressed, or a former container having a structure in which the object is sensed by a sensor such as infrared rays and discharged. Further, from an economical point of view, it is preferable that the foamer container has a structure that can be used repeatedly by removing the lid and filling the container with the composition.
[7.本発明の組成物]
本発明の組成物は、低級アルコール及びノニオン界面活性剤のみを含むものであってもよく、低級アルコール及びノニオン界面活性剤に加えて、酸、カチオン界面活性剤、水、保湿剤のうちいずれか1種以上を含むものであってもよいし、これらに加えてその他の成分を含んでもよい。その他の成分としては、例えば、増粘剤、植物由来成分、動物由来成分、香料を挙げることができる。また、本発明の組成物はフォーマーに充填し、泡を形成した状態で殺菌、除菌、消毒に必要な量を吐出でき、吐出した組成物を殺菌、除菌、消毒したい箇所に塗布して使用することができる。
[7. Composition of the present invention]
The composition of the present invention may contain only a lower alcohol and a nonionic surfactant, and in addition to the lower alcohol and nonionic surfactant, any one of an acid, a cationic surfactant, water, and a humectant It may contain one or more kinds, or it may contain other components in addition to these. Other ingredients include, for example, thickeners, plant-derived ingredients, animal-derived ingredients, and fragrances. In addition, the composition of the present invention can be filled into a foamer and discharged in the foamed state in the amount necessary for sterilization, sterilization, or disinfection, and the discharged composition can be applied to the area to be sterilized, sterilized, or disinfected. can be used.
本発明の組成物により形成される泡は、塗布した箇所になじみやすく、泡持ちに優れるものである。本発明において泡持ちとは、フォーマー容器からの吐出時に形成された泡が消えずに一定時間以上維持されることをいう。形成された泡の維持時間は、5秒以上が好ましく、10秒以上がより好ましく、吐出した組成物を均一に塗布できる観点から、15秒以上が特に好ましい。 The foam formed by the composition of the present invention easily adapts to the area where it is applied and has excellent foam retention. In the present invention, the term "foam retention" refers to the fact that the foam formed during discharge from the foamer container is maintained for a certain period of time or longer without disappearing. The maintenance time of the formed bubbles is preferably 5 seconds or more, more preferably 10 seconds or more, and particularly preferably 15 seconds or more from the viewpoint of uniformly applying the discharged composition.
また、本発明の組成物は、酸性に調整されていることが好ましい。具体的には、本発明の組成物はpH6以下が好ましく、pH5.5以下であることがより好ましく、pH5以下であることが特に好ましい。pHの下限は制限されず、通常pH1以上、好ましくはpH2以上、より好ましくはpH3以上である。 Further, the composition of the present invention is preferably adjusted to be acidic. Specifically, the composition of the present invention preferably has a pH of 6 or less, more preferably a pH of 5.5 or less, and particularly preferably a pH of 5 or less. The lower limit of pH is not limited and is usually pH 1 or higher, preferably pH 2 or higher, and more preferably pH 3 or higher.
[8.本発明の組成物の使用]
本発明の組成物は、殺菌、除菌、消毒用組成物として使用できる。殺菌とは、細菌を殺す効果のことを言い、除菌とは、菌を減らす効果のことを言い、消毒とは、ウイルス等の病原性のある微生物を死滅(不活性化)・除去させて害のない程度にする(無毒化する)ことを言う。本発明の組成物は、殺菌、除菌、消毒作用の機能がある旨の表示が可能であり、本発明に係る製品の本体、包装、説明書、宣伝物にその機能を記載することができる。本発明の組成物は、殺菌、除菌、消毒作用を得ることを目的とした範囲で利用され得るものであり、例えば、皮膚や硬質表面が挙げられる。皮膚としては、具体的には手、手首、指、爪などが挙げられる。硬質表面としては、例えばパソコン、マウス、キーボード、スマートフォン、タブレット、電話、プリンター、複写機、複合機、電卓、音響機器、映像機器などの情報機器;コップ、皿、スプーン、フォーク、箸などの食器;ペン、定規などの文房具;コップや皿などの食器;机、椅子、テーブル、カウンター、ロッカー、キャビネットなどの家具;ドア、ドアノブ、窓などの建具;リモコン等の備品;冷蔵庫、電子レンジなどの家電;スイッチ;蛇口;便器;手すり;床;など表面が硬く、日常生活において人の皮膚に触れるものが挙げられる。
[8. Use of the composition of the present invention]
The composition of the present invention can be used as a sterilizing, sterilizing, and disinfecting composition. Sterilization refers to the effect of killing bacteria, sterilization refers to the effect of reducing bacteria, and disinfection refers to the effect of killing (inactivating) or removing pathogenic microorganisms such as viruses. To make something harmless (to make it non-toxic). The composition of the present invention can be labeled as having sterilizing, sterilizing, and disinfecting functions, and these functions can be stated on the main body, packaging, instructions, and advertising materials of the product according to the present invention. . The composition of the present invention can be used for the purpose of providing sterilizing, sterilizing, and disinfecting effects, and includes, for example, skin and hard surfaces. Specific examples of the skin include hands, wrists, fingers, and nails. Examples of hard surfaces include information devices such as computers, mice, keyboards, smartphones, tablets, telephones, printers, copiers, multifunction devices, calculators, audio equipment, and video equipment; tableware such as cups, plates, spoons, forks, and chopsticks. ; Stationery such as pens and rulers; Tableware such as cups and plates; Furniture such as desks, chairs, tables, counters, lockers, and cabinets; Fittings such as doors, doorknobs, and windows; Equipment such as remote controls; Refrigerators, microwave ovens, etc. Household appliances; switches; faucets; toilets; handrails; floors; and other items with hard surfaces that come into contact with people's skin in daily life.
本発明の組成物を殺菌、除菌、消毒用組成物として使用する場合、その殺菌、除菌、消毒対象は特に制限されないが、例えばインフルエンザウイルス(例えばA型、B型等)、風疹ウイルス、エボラウイルス、コロナウイルス、麻疹ウイルス、水痘・帯状疱疹ウイルス、ヘルペスウイルス、ムンプスウイルス、アルボウイルス、RSウイルス、SARSウイルス、肝炎ウイルス(例えば、B型肝炎ウイルス、C型肝炎ウイルス等)、黄熱ウイルス、エイズウイルス、狂犬病ウイルス、ハンタウイルス、デングウイルス、ニパウイルス、リッサウイルス等のエンベロープウイルス(エンベロープを有するウイルス); アデノウイルス、ノロウイルス、ロタウイルス、ヒトパピローマウイルス、ポリオウイルス、エンテロウイルス、コクサッキーウイルス、ヒトパルボウイルス、脳心筋炎ウイルス、ライノウイルス等の非エンベロープウイルス(エンベロープを有さないウイルス);コレラ菌、サルモネラ菌、大腸菌、レジオネラ菌、炭疽菌、ヘリコバクターピロリ菌、リステリア菌、結核菌、非結核性抗酸菌、ブドウ球菌、連鎖球菌、肺炎球菌、髄膜炎菌、肺炎桿菌、セラチア菌、ジフテリア菌、ブルセラ菌、バルトネラ-ヘンセレ、エリジペロスリックス-ルシオパシエ、放線菌、ライム病菌、ウェルシュ菌、赤痢菌、ペスト菌、破傷風菌、エンテロバクター菌等の感染症に係る細菌;カンジダ、アスペルギルス、クリプトコッカス、ブラストミセス、コクシジオイデス、ヒストプラスマ、パラコクシジオイデス、スポロトリクス等の感染症に係る真菌等が挙げられる。これらの中でも、好ましくはエンベロープウイルスが挙げられ、より好ましくはインフルエンザウイルス、ヘルペスウイルス、コロナウイルス等が挙げられる。 When the composition of the present invention is used as a composition for sterilization, sterilization, or disinfection, the objects to be sterilized, sterilized, or disinfected are not particularly limited, but include, for example, influenza viruses (e.g., type A, type B, etc.), rubella virus, Ebola virus, coronavirus, measles virus, varicella/shingles virus, herpes virus, mumps virus, arbovirus, respiratory syncytial virus, SARS virus, hepatitis virus (e.g., hepatitis B virus, hepatitis C virus, etc.), yellow fever virus , AIDS virus, rabies virus, hantavirus, dengue virus, Nipah virus, lyssavirus, and other enveloped viruses; adenovirus, norovirus, rotavirus, human papillomavirus, poliovirus, enterovirus, coxsackie virus, human parvovirus, cerebrocardial virus Non-enveloped viruses (viruses that do not have envelopes) such as inflammatory viruses and rhinoviruses; Vibrio cholerae, Salmonella enterica, Escherichia coli, Legionella bacteria, Bacillus anthrax, Helicobacter pylori, Listeria monocytogenes, Mycobacterium tuberculosis, non-tuberculous mycobacteria, grapevine Coccus, Streptococcus, Streptococcus pneumoniae, Neisseria meningitidis, Klebsiella pneumoniae, Serratia monocytogenes, Diphtheria monocytogenes, Brucella monocytogenes, Bartonella hensele, Erysiperoshrix rhusiopathiae, Actinomycetes, Lyme disease, Clostridium perfringens, Shigella, Yersinia pestis Bacteria associated with infectious diseases such as Clostridium tetani and Enterobacter; Fungi associated with infectious diseases such as Candida, Aspergillus, Cryptococcus, Blastomyces, Coccidioides, Histoplasma, Paracoccidioides, and Sporothrix. Among these, enveloped viruses are preferred, and influenza viruses, herpes viruses, coronaviruses, and the like are more preferred.
以下、本発明を実施例によりさらに詳細に説明するが、本発明はこれら実施例に限定されるものではなく、本発明の課題を解決し得る限り、本発明は種々の態様をとることができる。 Hereinafter, the present invention will be explained in more detail with reference to Examples, but the present invention is not limited to these Examples, and the present invention can take various embodiments as long as the problems of the present invention can be solved. .
実施例1~2:抗ウイルス作用の評価
下記表1に記載の組成に従って、低級アルコール及びノニオン界面活性剤を含有する組成物を製造した。表に記載の配合量は、質量%を示す。具体的には、各成分を常温で均一に撹拌し、組成物を得た。得られた組成物について、抗ウイルス作用の評価を行った。
Examples 1-2: Evaluation of antiviral effect A composition containing a lower alcohol and a nonionic surfactant was produced according to the composition shown in Table 1 below. The blending amounts listed in the table indicate mass %. Specifically, each component was uniformly stirred at room temperature to obtain a composition. The antiviral effect of the obtained composition was evaluated.
<抗ウイルス作用>
SARS-CoV-2 Inhibitor screening Kit(Acro Biosystems)を使用し、新型コロナウイルスSARS-CoV-2のスパイク(S)タンパク質とヒト細胞膜に局在するアンジオテンシン変換酵素2(ACE2)タンパク質の結合阻害活性を評価した。具体的には以下の手順によって評価した。まず、以下の通りにバッファーを調製した。コーティングバッファー:15mM 炭酸ナトリウム(ナカライテスク)、35mM 炭酸水素ナトリウム(SIGMA)を超純水に溶解した(pH9.6)。洗浄バッファー:Phosphate Buffered Saline with Tween 20 Tablets(タカラバイオ) 1錠を超純水1Lに溶解した。ブロッキングバッファー:Blocker(TM) BSA (10X) in PBS(Thermo Scientific(TM))を洗浄バッファーで5倍希釈した。サンプルバッファー:ブロッキングバッファーを洗浄バッファーで4倍希釈した。次に、SARS-CoV-2 Sタンパク質RBDワーキング溶液(0.5 μg / mL)をブランク以外の各ウェルに100 μlずつ添加し、4℃で一晩インキュベートしてSタンパク質をウェルにコーティングした。ウェルを洗浄し、ブロッキングバッファーを300 μlずつ添加し、37℃で1.5時間インキュベートしてブロッキングした。ウェルを洗浄し、ビオチン化ヒトACE2ワーキング溶液(0.12 μg / mL)をブランク以外の各ウェルに50 μlずつ(ブランクウェルにはサンプルバッファー 50 μlを添加)、サンプルバッファーで2倍希釈した被験物質をポジティブコントロール及びブランク以外の各ウェルに50 μlずつ添加し(ポジティブコントロールとブランクのウェルにはサンプルバッファー 50 μlを添加)、37℃で1時間インキュベートしてSタンパク質とACE2を結合させた。ウェルを洗浄し、ストレプトアビジン-HRPワーキング溶液(0.1 μg/mL)を100 μlずつ添加し、遮光して37℃で1時間インキュベートしてビオチン化ヒトACE2を標識した。ウェルを洗浄し、TMB溶液(富士フィルム和光純薬)を100 μlずつ添加し、遮光して37℃で20分間インキュベートしてHRPに反応させた。0.3M 硫酸を100 μlずつ添加して反応を停止させ、プレートリーダー(SpectraMax i3x、モレキュラーデバイス)で450 nmの吸光度を測定した。以下の計算式を用いて、阻害率を算出した。
阻害率(%) = 100-{(Date sample-Date blank)/(Date positive control-Date blank)}×100
(Date sample:被験物質ありでSタンパク質とACE2を反応させた吸光度
Date blank:被験物質ありでSタンパク質を添加せずに同じ操作をした吸光度
Date positive control:被験物質なしでSタンパク質とACE2を反応させた吸光度
Date blank:被験物質なしでSタンパク質を添加せずに同じ操作をした吸光度)
結果を表1に示す。
<Antiviral effect>
Using the SARS-CoV-2 Inhibitor Screening Kit (Acro Biosystems), we investigated the binding inhibitory activity between the spike (S) protein of the novel coronavirus SARS-CoV-2 and the angiotensin-converting enzyme 2 (ACE2) protein localized in the human cell membrane. evaluated. Specifically, the evaluation was performed according to the following procedure. First, a buffer was prepared as follows. Coating buffer: 15mM sodium carbonate (Nacalai Tesque) and 35mM sodium bicarbonate (SIGMA) were dissolved in ultrapure water (pH 9.6). Washing buffer: Phosphate Buffered Saline with Tween 20 Tablets (Takara Bio) 1 tablet was dissolved in 1 L of ultrapure water. Blocking buffer: Blocker (TM) BSA (10X) in PBS (Thermo Scientific (TM)) was diluted 5 times with washing buffer. Sample buffer: Blocking buffer was diluted 4 times with wash buffer. Next, 100 μl of SARS-CoV-2 S protein RBD working solution (0.5 μg/mL) was added to each well except the blank and incubated overnight at 4°C to coat the S protein on the wells. The wells were washed, 300 μl of blocking buffer was added, and the wells were incubated at 37° C. for 1.5 hours for blocking. Wash the wells, add 50 μl of biotinylated human ACE2 working solution (0.12 μg/mL) to each well except the blank (add 50 μl of sample buffer to the blank well), and add the test substance diluted 2 times with sample buffer. 50 μl was added to each well other than the positive control and blank (50 μl of sample buffer was added to the positive control and blank wells), and incubated at 37°C for 1 hour to allow binding of S protein and ACE2. The wells were washed, 100 μl of streptavidin-HRP working solution (0.1 μg/mL) was added, and biotinylated human ACE2 was labeled by incubating at 37°C for 1 hour in the dark. The wells were washed, 100 μl of TMB solution (Fuji Film Wako Pure Chemical Industries, Ltd.) was added to each well, and incubated at 37°C for 20 minutes in the dark to react with HRP. The reaction was stopped by adding 100 μl of 0.3M sulfuric acid, and the absorbance at 450 nm was measured using a plate reader (SpectraMax i3x, Molecular Devices). The inhibition rate was calculated using the following formula.
Inhibition rate (%) = 100-{(Date sample-Date blank)/(Date positive control-Date blank)}×100
(Date sample: Absorbance of S protein and ACE2 reacted with test substance
Date blank: Absorbance obtained by the same operation with the test substance but without adding S protein
Date positive control: Absorbance of S protein and ACE2 reacted without test substance
Date blank: Absorbance obtained by performing the same procedure without the test substance and without adding S protein)
The results are shown in Table 1.
抗ウイルス作用の評価は、病原性のあるウイルスをどの程度無毒化できるかを示すため、消毒作用の評価として使用できる。ウイルス感染は、ウイルスが宿主細胞表面に結合し、細胞内に侵入することで起こるため、ウイルスと宿主細胞の結合を阻害する成分等は、ウイルス感染に対して抑制作用をもつと考えられる。新型コロナウイルスSARS-CoV-2は、ウイルスのエンベロープに存在するSタンパク質とヒト細胞膜上に存在するACE2タンパク質の特異的な結合を介して、ヒト細胞と結合することが知られている。本試験では、新型コロナウイルスSARS-CoV-2をモデルとして用いたSタンパク質とACE2タンパク質間の相互作用試験により、組成物の抗ウイルス作用を評価した。本試験結果より、エタノールが30質量%~50質量%であり、ノニオン界面活性剤を配合した本願発明の組成物実施例1,2は、ノニオン界面活性剤のみを配合する比較例1や、エタノールが20質量%である比較例2と比べて優れた抗ウイルス活性を示すことがわかる。このことから、低級アルコールを30~60質量%、及び、ノニオン界面活性剤を含有する本願発明の組成物は、優れた抗ウイルス作用(すなわち、消毒作用)を示すことがわかる。 Evaluation of antiviral effect shows the extent to which pathogenic viruses can be rendered nontoxic, so it can be used as an evaluation of disinfection effect. Viral infection occurs when the virus binds to the host cell surface and invades into the cell, so components that inhibit the binding between the virus and the host cell are thought to have a suppressive effect on viral infection. The novel coronavirus SARS-CoV-2 is known to bind to human cells through a specific bond between the S protein present in the virus envelope and the ACE2 protein present on the human cell membrane. In this study, the antiviral effect of the composition was evaluated by an interaction test between S protein and ACE2 protein using the new coronavirus SARS-CoV-2 as a model. From the test results, composition examples 1 and 2 of the present invention in which ethanol is 30% to 50% by mass and a nonionic surfactant are blended, comparative example 1 in which only a nonionic surfactant is blended, and ethanol It can be seen that it exhibits superior antiviral activity compared to Comparative Example 2 in which the amount is 20% by mass. This shows that the composition of the present invention containing 30 to 60% by mass of lower alcohol and a nonionic surfactant exhibits excellent antiviral action (ie, disinfecting action).
実施例3~10:使用感の評価
下記表2に記載の組成に従って、低級アルコール及びノニオン界面活性剤を含有する組成物を製造した。表に記載の配合量は、質量%を示す。具体的には、各成分を常温で均一に撹拌し、組成物を得た。得られた組成物を、フォーマー容器に充填し、吐出時の泡質、泡吐出時の使用感を下記の要領で評価した。結果を表2に示す。
<泡質>
・〇:保形性のある泡ができる(15秒以上保持)
・△:気泡するが、泡に十分な保形性がない(5~14秒)
・×:気泡しない/気泡してもすぐに消泡する
<泡吐出時の使用感>
・〇:皮膚への塗布時にべたつかない
・△:皮膚への塗布時にややべたつく
・×:皮膚への塗布時にべたつく
Examples 3 to 10: Evaluation of feeling in use Compositions containing a lower alcohol and a nonionic surfactant were produced according to the compositions shown in Table 2 below. The blending amounts listed in the table indicate mass %. Specifically, each component was uniformly stirred at room temperature to obtain a composition. The resulting composition was filled into a foamer container, and the quality of foam upon discharge and the feeling of use upon discharge of foam were evaluated in the following manner. The results are shown in Table 2.
<Foam quality>
・〇: Forms foam with shape retention (held for 15 seconds or more)
・△: Bubbles are formed, but the bubbles do not have sufficient shape retention (5 to 14 seconds)
・×: No bubbles / Even if bubbles are formed, they disappear immediately <Feeling when dispensing bubbles>
・〇: Not sticky when applied to the skin ・△: Slightly sticky when applied to the skin
・×: Sticky when applied to the skin
表2より、比較例3~5は気泡せず、泡吐出時の使用感は評価できなかった。一方、エタノールを30~40質量%配合し、ノニオン界面活性剤を配合する実施例3~10は、比較例3~5と比べて保形成のある泡を形成でき、べたつきがほとんどなく、使用感に優れるものであった。このことから、低級アルコールを30~60質量%、及び、ノニオン界面活性剤を含有する本願発明の組成物は、泡質、吐出時の使用感に優れた組成物であることがわかる。 From Table 2, Comparative Examples 3 to 5 did not produce bubbles, and the feeling of use when discharging bubbles could not be evaluated. On the other hand, Examples 3 to 10 containing 30 to 40% by mass of ethanol and a nonionic surfactant were able to form foam with better retention compared to Comparative Examples 3 to 5, had almost no stickiness, and had a feeling of use. It was excellent. From this, it can be seen that the composition of the present invention containing 30 to 60% by mass of a lower alcohol and a nonionic surfactant is a composition with excellent foam quality and feel during discharge.
実施例11~17:使用感の評価
下記表3に記載の組成に従って、低級アルコール、ノニオン界面活性剤、酸、カチオン界面活性剤及び保湿剤を含有する組成物を製造した。表に記載の配合量は、質量%を示す。具体的には、各成分を常温で均一に撹拌し、組成物を得た。得られた組成物を、フォーマー容器に充填し、吐出時の泡質、泡吐出時の使用感を下記の要領で評価した。結果を表3に示す。
<泡質>
・〇:保形性のある泡ができる(15秒以上保持)
・△:気泡するが、泡に十分な保形性がない(5~14秒)
・×:気泡しない/気泡してもすぐに消泡する
<泡吐出時の使用感>
・〇:皮膚への塗布時にべたつかない
・△:皮膚への塗布時にややべたつく
・×:皮膚への塗布時にべたつく
Examples 11 to 17: Evaluation of feeling in use Compositions containing a lower alcohol, a nonionic surfactant, an acid, a cationic surfactant, and a humectant were produced according to the compositions shown in Table 3 below. The blending amounts listed in the table indicate mass %. Specifically, each component was uniformly stirred at room temperature to obtain a composition. The resulting composition was filled into a foamer container, and the quality of foam upon discharge and the feeling of use upon discharge of foam were evaluated in the following manner. The results are shown in Table 3.
<Foam quality>
・〇: Forms foam with shape retention (held for 15 seconds or more)
・△: Bubbles are formed, but the bubbles do not have sufficient shape retention (5 to 14 seconds)
・×: No bubbles / Even if bubbles are formed, they disappear immediately <Feeling when dispensing bubbles>
・〇: Not sticky when applied to the skin ・△: Slightly sticky when applied to the skin
・×: Sticky when applied to the skin
表3より、エタノールを40質量%配合し、ノニオン界面活性剤を配合する実施例11~17は、保形成のある泡を形成でき、べたつきがなく、使用感に優れるものであった。このことから、低級アルコール30~60質量%、ノニオン界面活性剤、酸、カチオン界面活性剤及び保湿剤を含有する本願発明の組成物は、泡質、吐出時の使用感に優れた組成物であることがわかる。 From Table 3, Examples 11 to 17, in which 40% by mass of ethanol was blended and a nonionic surfactant was blended, were able to form foam with retention, were non-sticky, and had an excellent feeling of use. From this, the composition of the present invention containing 30 to 60% by mass of lower alcohol, a nonionic surfactant, an acid, a cationic surfactant, and a humectant is a composition with excellent foam quality and feel when dispensing. I understand that there is something.
実施例18
エタノール40質量%、塩化ベンザルコニウム0.05質量%、ポリオキシエチレンオクチルドデシルエーテル1.0質量%、グリセリン2質量%、 及び水(残部)を常温で均一に撹拌して本発明の組成物を製造し、得られた組成物をフォーマー容器に充填した。得られた組成物をフォーマー容器から吐出したところ、泡の状態で吐出され、その保持時間は15秒以上と長いものであった。泡状の組成物は液だれを起こさず、皮膚や硬質表面に均一に塗布が可能であり、殺菌・消毒作用を有するものである。
Example 18
The composition of the present invention is prepared by uniformly stirring 40% by mass of ethanol, 0.05% by mass of benzalkonium chloride, 1.0% by mass of polyoxyethylene octyl dodecyl ether, 2% by mass of glycerin, and water (the remainder) at room temperature. The resulting composition was filled into a former container. When the obtained composition was discharged from the former container, it was discharged in the form of foam, and the retention time was as long as 15 seconds or more. The foam composition does not cause dripping, can be applied uniformly to the skin or hard surfaces, and has sterilizing and disinfecting effects.
実施例19
エタノール50質量%、イソプロパノール5質量%、塩化ベンゼトニウム0.05質量%、ソルビタン脂肪酸エステル1.0質量%、グリセリン2質量%、 ジグリセリン1質量%及び水(残部)を常温で均一に撹拌して本発明の組成物を製造し、得られた組成物をフォーマー容器に充填した。得られた組成物をフォーマー容器から吐出すると、泡の状態で吐出され、その保持時間は長いものである。泡状の組成物は液だれを起こさず、皮膚や硬質表面に均一に塗布が可能であり、殺菌・消毒作用を有するものである。
Example 19
50% by mass of ethanol, 5% by mass of isopropanol, 0.05% by mass of benzethonium chloride, 1.0% by mass of sorbitan fatty acid ester, 2% by mass of glycerin, 1% by mass of diglycerin and water (the remainder) were uniformly stirred at room temperature. A composition of the present invention was produced, and the resulting composition was filled into a former container. When the obtained composition is discharged from a foamer container, it is discharged in the form of foam, and its retention time is long. The foam composition does not cause dripping, can be applied uniformly to the skin or hard surfaces, and has sterilizing and disinfecting effects.
実施例20
エタノール60質量%、次亜塩素酸ナトリウム0.04質量%、ポリオキシエチレンベヘニルエーテル1.5質量%、グリセリン2質量%及び水(残部)を常温で均一に撹拌して本発明の組成物を製造し、得られた組成物をフォーマー容器に充填した。得られた組成物をフォーマー容器から吐出すると、泡の状態で吐出され、その保持時間は長いものである。泡状の組成物は液だれを起こさず、皮膚や硬質表面に均一に塗布が可能であり、殺菌・消毒作用を有するものである。
Example 20
The composition of the present invention was prepared by uniformly stirring 60% by mass of ethanol, 0.04% by mass of sodium hypochlorite, 1.5% by mass of polyoxyethylene behenyl ether, 2% by mass of glycerin, and water (the remainder) at room temperature. The resulting composition was filled into a former container. When the obtained composition is discharged from a foamer container, it is discharged in the form of foam, and its retention time is long. The foam composition does not cause dripping, can be applied uniformly to the skin or hard surfaces, and has sterilizing and disinfecting effects.
実施例23
エタノール60質量%、ラウリルジメチルアミンN-オキシド0.1質量%、ポリオキシエチレンラウリルエーテル1質量%、クエン酸0.2質量%、グリセリン2質量%及び水(残部)を常温で均一に撹拌して本発明の組成物を製造し、得られた組成物をフォーマー容器に充填した。得られた組成物をフォーマー容器から吐出すると、泡の状態で吐出され、その保持時間は長いものである。泡状の組成物は液だれを起こさず、皮膚や硬質表面に均一に塗布が可能であり、殺菌・消毒作用を有するものである。
Example 23
60% by mass of ethanol, 0.1% by mass of lauryl dimethylamine N-oxide, 1% by mass of polyoxyethylene lauryl ether, 0.2% by mass of citric acid, 2% by mass of glycerin, and water (the remainder) were uniformly stirred at room temperature. The composition of the present invention was manufactured using the same method, and the obtained composition was filled into a former container. When the obtained composition is discharged from a foamer container, it is discharged in the form of foam, and its retention time is long. The foam composition does not cause dripping, can be applied uniformly to the skin or hard surfaces, and has sterilizing and disinfecting effects.
本発明の組成物は、低級アルコールを含有しながらも、泡持ちが良く、使用感に優れ、かつ、殺菌・抗ウイルスに優れたものであることから、産業上の有用性は高い。 Although the composition of the present invention contains a lower alcohol, it has good foam retention, is comfortable to use, and has excellent bactericidal and antiviral properties, and therefore has high industrial utility.
Claims (1)
(ただし、以下(1)~(6)の組成物を除く。
(1)リジン、セリン、及びdl-ピロリドンカルボン酸ナトリウムから選ばれる少なくとも1種を含有する組成物
(2)アルカリ剤を含有する組成物
(3)ビス-PEG/PPG-[14-20]/[5-20]-ジメチコンを含む、シリコーンベースの界面活性剤を含有する組成物
(4)臨界温度が0~50℃の噴射剤を含有するエアゾール組成物
(5)HLB9~16のモノステアリン酸ポリオキシエチレングリセリン又はHLB9~16のモノステアリン酸ポリエチレングリコールを含有する組成物
(6)銅イオンを放出する銅イオン源材料又は亜鉛イオンを放出する亜鉛イオン源材料から選択される金属イオン源材料を含む組成物) A composition that is used by discharging it in the form of a foam from a foamer container, and contains a lower alcohol selected from ethanol and isopropanol , a nonionic surfactant, an acid (excluding citric acid), and a cationic surfactant. , the nonionic surfactant is at least one selected from polyoxyethylene polyoxypropylene alkyl ether, polyoxyalkylene sorbitan fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, and glycerin fatty acid ester, and contains the lower alcohol. A composition characterized in that the amount is 30-60% by weight.
(However, the following compositions (1) to (6) are excluded.
(1) Composition containing at least one selected from lysine, serine, and sodium dl-pyrrolidonecarboxylate (2) Composition containing an alkaline agent (3) Bis-PEG/PPG-[14-20]/ [5-20] Composition containing a silicone-based surfactant, including dimethicone (4) Aerosol composition containing a propellant with a critical temperature of 0 to 50° C. (5) Monostearic acid with HLB 9 to 16 Composition containing polyoxyethylene glycerin or polyethylene glycol monostearate with HLB 9 to 16 (6) A metal ion source material selected from a copper ion source material that releases copper ions or a zinc ion source material that releases zinc ions. (composition containing)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022145410A JP7345933B2 (en) | 2020-05-25 | 2022-09-13 | Alcohol-containing composition |
JP2023139023A JP2023159411A (en) | 2020-05-25 | 2023-08-29 | Alcohol-containing composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020090894 | 2020-05-25 | ||
JP2020090894 | 2020-05-25 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022145410A Division JP7345933B2 (en) | 2020-05-25 | 2022-09-13 | Alcohol-containing composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021187846A JP2021187846A (en) | 2021-12-13 |
JP7345886B2 true JP7345886B2 (en) | 2023-09-19 |
Family
ID=78848929
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021086582A Active JP7345886B2 (en) | 2020-05-25 | 2021-05-24 | Alcohol-containing composition |
JP2022145410A Active JP7345933B2 (en) | 2020-05-25 | 2022-09-13 | Alcohol-containing composition |
JP2023139023A Pending JP2023159411A (en) | 2020-05-25 | 2023-08-29 | Alcohol-containing composition |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022145410A Active JP7345933B2 (en) | 2020-05-25 | 2022-09-13 | Alcohol-containing composition |
JP2023139023A Pending JP2023159411A (en) | 2020-05-25 | 2023-08-29 | Alcohol-containing composition |
Country Status (1)
Country | Link |
---|---|
JP (3) | JP7345886B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7516327B2 (en) * | 2021-09-02 | 2024-07-16 | 花王株式会社 | Disinfection products |
JP7523138B2 (en) * | 2021-11-18 | 2024-07-26 | 株式会社ニューギン | Gaming Machines |
JP7523137B2 (en) * | 2021-11-18 | 2024-07-26 | 株式会社ニューギン | Gaming Machines |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001139993A (en) | 1999-11-17 | 2001-05-22 | Fumakilla Ltd | Skin disinfectant cleaner |
JP2005232113A (en) | 2004-02-23 | 2005-09-02 | Lion Corp | Hair cosmetic |
JP2005530857A (en) | 2002-06-21 | 2005-10-13 | ザ プロクター アンド ギャンブル カンパニー | Antibacterial compositions, antibacterial products, and methods of using them |
JP2007506684A (en) | 2003-09-29 | 2007-03-22 | エセナ ヘルスケア インコーポレーテッド | Gel-like composition and forming composition with high alcohol content |
JP2008255101A (en) | 2007-03-09 | 2008-10-23 | Maruishi Pharmaceutical Co Ltd | disinfectant |
WO2009075142A1 (en) | 2007-12-12 | 2009-06-18 | Lion Corporation | Bactericidal cleanser composition |
JP2014009201A (en) | 2012-06-29 | 2014-01-20 | Lion Corp | Leave-in bactericidal cleanser composition |
US20160158122A1 (en) | 2012-11-30 | 2016-06-09 | Reckitt & Colman (Overseas) Limited | Microbicidal Personal Care Compositions Comprising Metal Ions |
JP2018008934A (en) | 2016-07-01 | 2018-01-18 | サラヤ株式会社 | Foamable composition having anti-virus action |
JP2019189652A (en) | 2018-04-05 | 2019-10-31 | 株式会社ニイタカ | Foamer composition, foamer with foamer composition, disinfection method using foamer composition, and cleaning method using foamer composition |
JP2022027325A (en) | 2020-07-31 | 2022-02-10 | 丸石製薬株式会社 | Low concentration ethanol-containing acidic foam formation composition |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0759482B2 (en) * | 1985-07-10 | 1995-06-28 | 武田薬品工業株式会社 | Disinfectant |
JPH06279268A (en) * | 1993-01-27 | 1994-10-04 | Takeda Chem Ind Ltd | Disinfecting and sterilizing agent and aerosol composition containing the same |
JPH06327750A (en) * | 1993-05-24 | 1994-11-29 | Osaka Zosenjo:Kk | Aerosol composition for sterilization and disinfection |
JPH07285808A (en) * | 1993-12-18 | 1995-10-31 | Japan Metals & Chem Co Ltd | Foamable alcohol composition |
JPH11292710A (en) * | 1998-04-03 | 1999-10-26 | T Pooru Kk | Fungicide composition |
JP5565902B2 (en) * | 2010-04-08 | 2014-08-06 | 花王株式会社 | Hand sanitizer composition |
EP3413770B1 (en) * | 2016-02-11 | 2024-10-09 | Gojo Industries, Inc. | High quality non-aerosol hand sanitizing foam |
JP7096637B2 (en) * | 2016-02-22 | 2022-07-06 | 株式会社ニイタカ | Disinfectant composition and cleaning sterilization method |
MX2019015822A (en) * | 2017-06-28 | 2022-09-05 | Collidion Inc | COMPOSITIONS, METHODS AND USES FOR CLEANING, DISINFECTION AND/OR STERILIZATION. |
-
2021
- 2021-05-24 JP JP2021086582A patent/JP7345886B2/en active Active
-
2022
- 2022-09-13 JP JP2022145410A patent/JP7345933B2/en active Active
-
2023
- 2023-08-29 JP JP2023139023A patent/JP2023159411A/en active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001139993A (en) | 1999-11-17 | 2001-05-22 | Fumakilla Ltd | Skin disinfectant cleaner |
JP2005530857A (en) | 2002-06-21 | 2005-10-13 | ザ プロクター アンド ギャンブル カンパニー | Antibacterial compositions, antibacterial products, and methods of using them |
JP2007506684A (en) | 2003-09-29 | 2007-03-22 | エセナ ヘルスケア インコーポレーテッド | Gel-like composition and forming composition with high alcohol content |
JP2005232113A (en) | 2004-02-23 | 2005-09-02 | Lion Corp | Hair cosmetic |
JP2008255101A (en) | 2007-03-09 | 2008-10-23 | Maruishi Pharmaceutical Co Ltd | disinfectant |
WO2009075142A1 (en) | 2007-12-12 | 2009-06-18 | Lion Corporation | Bactericidal cleanser composition |
JP2014009201A (en) | 2012-06-29 | 2014-01-20 | Lion Corp | Leave-in bactericidal cleanser composition |
US20160158122A1 (en) | 2012-11-30 | 2016-06-09 | Reckitt & Colman (Overseas) Limited | Microbicidal Personal Care Compositions Comprising Metal Ions |
JP2018008934A (en) | 2016-07-01 | 2018-01-18 | サラヤ株式会社 | Foamable composition having anti-virus action |
JP2019189652A (en) | 2018-04-05 | 2019-10-31 | 株式会社ニイタカ | Foamer composition, foamer with foamer composition, disinfection method using foamer composition, and cleaning method using foamer composition |
JP2022027325A (en) | 2020-07-31 | 2022-02-10 | 丸石製薬株式会社 | Low concentration ethanol-containing acidic foam formation composition |
Also Published As
Publication number | Publication date |
---|---|
JP2023159411A (en) | 2023-10-31 |
JP7345933B2 (en) | 2023-09-19 |
JP2021187846A (en) | 2021-12-13 |
JP2022171791A (en) | 2022-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7345933B2 (en) | Alcohol-containing composition | |
US11998575B2 (en) | Sanitizer composition with probiotic/prebiotic active ingredient | |
JP7195655B2 (en) | Effervescent composition with antiviral activity | |
US11564879B2 (en) | Sanitizer composition with probiotic/prebiotic active ingredient | |
JP2020519708A (en) | Alcohol containing non-antibacterial cleaning composition | |
AU2013255558A1 (en) | Foaming formulations including silicone polyesters | |
US20230218491A1 (en) | Methods and compounds for increasing virucidal efficacy in hydroalcoholic systems | |
US20180140540A1 (en) | Topical cleansing composition with prebiotic/probiotic additive | |
JP2022505611A (en) | Alcohol containing biofilm-inhibiting non-antibacterial cleaning composition | |
JP4410903B2 (en) | Gel-like hand sterilization detergent composition | |
JP2007070469A (en) | Cleaner composition | |
JP2011079765A (en) | Liquid detergent | |
CN108441350A (en) | A kind of kitchen cleaning agent and preparation method thereof based on bio-based compounds | |
US20220264885A1 (en) | Antimicrobial compositions | |
JP6382012B2 (en) | Foam lotion | |
JP2005306752A (en) | Body cleaning composition for foam discharge container | |
EP4223367A1 (en) | Carbonated aerosol external preparation for skin | |
JP2003292995A (en) | Cleanser composition | |
JP2022026765A (en) | Virus inactivating agent composition | |
JP7045750B1 (en) | Alcohol-based rubbing-type hand disinfection composition with improved usability | |
JP2024070580A (en) | Antibacterial antiseptic solution | |
JP2025013252A (en) | Antibacterial agent composition | |
JP2024075393A (en) | Disinfectant Composition | |
WO2023120630A1 (en) | Disinfectant composition | |
JP2005306914A (en) | Cleaning composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211021 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20211021 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220328 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220627 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220825 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20220902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220913 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230131 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230403 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230530 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230801 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230830 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7345886 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |